Baseline patient characteristics
| . | Overall . | MDS . | CMML . | P value . |
|---|---|---|---|---|
| n (% or IQR) | 100 | 82 | 18 | |
| Age, y | 69.0 (62.5-75.0) | 68.0 (60.2-74.8) | 72.5 (69.0-75.8) | .057 |
| Male | 62 (62.0) | 53 (64.6) | 9 (50.0) | .373 |
| Hemoglobin, g/dL | 9.3 (8.4-10.1) | 9.2 (8.5-10.0) | 9.5 (8.3-10.9) | .555 |
| Platelets, ×109 cells per L | 52.0 (21.5-104.0) | 53.0 (22.0-98.0) | 48.0 (21.8-194.5) | .615 |
| ANC, ×109 cells per L | 0.9 (0.5-1.8) | 0.8 (0.4-1.5) | 2.8 (1.7-9.8) | <.001 |
| BM blast, % | 10.0 (5.0-14.8) | 9.0 (4.0-14.2) | 11.5 (10.0-14.2) | .039 |
| Complex cytogenetics | 38 (38.4) | 36 (43.9) | 2 (11.8) | .027 |
| Cytogenetic risk category | ||||
| Very good | 1 (1.2) | .148 | ||
| Good | 20 (24.7) | |||
| Intermediate | 12 (14.8) | |||
| Poor | 12 (14.8) | |||
| Very poor | 36 (44.4) | |||
| WHO fifth edition | ||||
| MDS-f | 2 (2.4) | <.001 | ||
| MDS-IB1 | 14 (17.1) | |||
| MDS-IB2 | 33 (40.2) | |||
| MDS-LB | 11 (13.4) | |||
| MDS-LB-SF3B1 | 1 (1.2) | |||
| MDS-biTP53 | 21 (25.6) | |||
| MD-CMML | 7 (38.9) | |||
| MP-CMML | 11 (61.1) | |||
| IPSS-R | ||||
| Low | 2 (2.5) | .283 | ||
| Intermediate | 8 (9.9) | |||
| High | 27 (33.3) | |||
| Very high | 44 (54.3) | |||
| IPSS-M | ||||
| Low | 2 (2.4) | .058 | ||
| Moderate low | 3 (3.7) | |||
| Moderate high | 6 (7.3) | |||
| High | 22 (26.8) | |||
| Very high | 49 (59.8) | |||
| TP53∗ | 33 (33.7) | 30 (38.5) | 2 (11.8) | .068 |
| TP53 multihit† | 21 (21.4) | 21 (26.2) | ||
| Mutational ontology‡ | ||||
| Chromatin remodeling | 8 (8.0) | 6 (7.3) | 2 (11.1) | <.001 |
| DNA methylation | 7 (7.0) | 6 (7.3) | 1 (5.6) | |
| Other mutations | 18 (18.0) | 17 (20.7) | 1 (5.6) | |
| RAS signaling | 14 (14.0) | 6 (7.3) | 8 (44.4) | |
| Spliceosome | 2 (2.0) | 1 (1.2) | 1 (5.6) | |
| Transcription factors | 18 (18.0) | 16 (19.5) | 2 (11.1) | |
| R. tyrosine kinase | 1 (1.0) | 1 (5.6) |
| . | Overall . | MDS . | CMML . | P value . |
|---|---|---|---|---|
| n (% or IQR) | 100 | 82 | 18 | |
| Age, y | 69.0 (62.5-75.0) | 68.0 (60.2-74.8) | 72.5 (69.0-75.8) | .057 |
| Male | 62 (62.0) | 53 (64.6) | 9 (50.0) | .373 |
| Hemoglobin, g/dL | 9.3 (8.4-10.1) | 9.2 (8.5-10.0) | 9.5 (8.3-10.9) | .555 |
| Platelets, ×109 cells per L | 52.0 (21.5-104.0) | 53.0 (22.0-98.0) | 48.0 (21.8-194.5) | .615 |
| ANC, ×109 cells per L | 0.9 (0.5-1.8) | 0.8 (0.4-1.5) | 2.8 (1.7-9.8) | <.001 |
| BM blast, % | 10.0 (5.0-14.8) | 9.0 (4.0-14.2) | 11.5 (10.0-14.2) | .039 |
| Complex cytogenetics | 38 (38.4) | 36 (43.9) | 2 (11.8) | .027 |
| Cytogenetic risk category | ||||
| Very good | 1 (1.2) | .148 | ||
| Good | 20 (24.7) | |||
| Intermediate | 12 (14.8) | |||
| Poor | 12 (14.8) | |||
| Very poor | 36 (44.4) | |||
| WHO fifth edition | ||||
| MDS-f | 2 (2.4) | <.001 | ||
| MDS-IB1 | 14 (17.1) | |||
| MDS-IB2 | 33 (40.2) | |||
| MDS-LB | 11 (13.4) | |||
| MDS-LB-SF3B1 | 1 (1.2) | |||
| MDS-biTP53 | 21 (25.6) | |||
| MD-CMML | 7 (38.9) | |||
| MP-CMML | 11 (61.1) | |||
| IPSS-R | ||||
| Low | 2 (2.5) | .283 | ||
| Intermediate | 8 (9.9) | |||
| High | 27 (33.3) | |||
| Very high | 44 (54.3) | |||
| IPSS-M | ||||
| Low | 2 (2.4) | .058 | ||
| Moderate low | 3 (3.7) | |||
| Moderate high | 6 (7.3) | |||
| High | 22 (26.8) | |||
| Very high | 49 (59.8) | |||
| TP53∗ | 33 (33.7) | 30 (38.5) | 2 (11.8) | .068 |
| TP53 multihit† | 21 (21.4) | 21 (26.2) | ||
| Mutational ontology‡ | ||||
| Chromatin remodeling | 8 (8.0) | 6 (7.3) | 2 (11.1) | <.001 |
| DNA methylation | 7 (7.0) | 6 (7.3) | 1 (5.6) | |
| Other mutations | 18 (18.0) | 17 (20.7) | 1 (5.6) | |
| RAS signaling | 14 (14.0) | 6 (7.3) | 8 (44.4) | |
| Spliceosome | 2 (2.0) | 1 (1.2) | 1 (5.6) | |
| Transcription factors | 18 (18.0) | 16 (19.5) | 2 (11.1) | |
| R. tyrosine kinase | 1 (1.0) | 1 (5.6) |